Keith Rabois - If You Can’t Sell Them, Compete with Them - [Invest Like the Best, EP.115]

Episode Summary

Executive Summary: Keith Raboi argues that the best startups and investments create asymmetric, vertically integrated advantages that get easier over time. In conversation with Patrick O'Shaughnessy, he covers anomaly-spotting, secrets, trust-building, recruiting talent, contrarian views on lean startup thinking, and why technology can simultaneously improve outcomes, experience, and cost.

Main Topics: Vertical integration as strategy (Priority: 5/5): Raboi favors owning the full stack to capture value and control destiny. Anomalies and secrets (Priority: 5/5): He looks for unusual signals and hidden beliefs that indicate transformative potential. Accumulating advantage (Priority: 5/5): Businesses should become easier to run over time via data, brand, or trust. Trust as a growth mechanism (Priority: 4/5): In regulated or skeptical markets, credibility must be engineered before brand exists. Contrarian critique of lean startup (Priority: 5/5): He rejects incremental iteration when the opportunity requires big, capital-intensive bets. Talent and founder evaluation (Priority: 4/5): The ability to recruit exceptional people is a central test of founder quality. Learning, career, and investing craft (Priority: 3/5): He contrasts operating vs investing and emphasizes osmosis, hard work, and reading.

Key Arguments: Vertical integration captures more value and avoids adoption risk; selling components often captures only 10%-30%. An investment needs something anomalous—team, tech, or market data—to have a real chance of being exceptional. The best businesses get easier every year; that is the essence of accumulated advantage. Trust can compound like a version of brand and materially reduce friction in healthcare and fintech. Lean startup can underfit transformative ideas; some winners need capital before product-market fit is proven. Founder quality shows up in recruiting: strong candidates should eagerly want to join. In startups, 10x ideas matter; 10% improvements are not enough to change outcomes. Technology can improve experience, reduce cost, and improve quality at the same time.

Data Points: Opendoor launch funding: $10 million - He cites this as a fat-startup example of funding the thesis upfront. Healthcare share of U.S. economy: 22% - Used to explain why healthcare is a huge innovation target. Investment mix: 70% - He says roughly 70% of his work is seed or Series A investing. Founder decision confidence: 70% conviction - He says executives often need to decide with about this level of confidence. Investor decision confidence: 10% to 50% - He describes early-stage investing as operating in this conviction range. Business value capture from selling components: 10% to 30% - He argues components often capture only a small fraction of value created. Early-stage pricing post-2015: 25 to 33% less than it was from 2013 to 15 - His rough estimate of early-stage price levels. Early-stage pricing earlier era: 2x what it was before, like 2008 to 2010, 12 kind of era - He compares current early-stage pricing to prior cycles. PayPal guarantee: $100,000 - Used to bootstrap trust for money movement. FDIC account coverage: up to $100,000 - He mentions qualifying accounts for insurance protection. Public market example: $3, $4 billion - He estimates Guardant Health's public valuation range.

Pivotal Quotes: "If your technology is better, but potential customers are too set in their ways to switch, use it yourself and compete with them." — Paul Graham: Opening framing quote that Raboi uses to justify vertical integration. "I tend to think of startups are more like a movie." — Keith Raboi: He explains his top-down view of company building through narrative, casting, production, and marketing. "I don't want 10%. If you're going to take two kids in a garage again and take over the world ... you need zeros on the dashboard." — Keith Raboi: He rejects incremental experimentation when aiming for category-defining outcomes.

Implications: For founders and investors, the open question is whether a given market can support a truly asymmetric, compounding advantage before capital and time run out.